← Back to Search

NMDA-antagonist

Nitrous Oxide for Depression

Phase 2
Recruiting
Led By Paul Myles, MD
Research Sponsored by Bayside Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 24 hours
Awards & highlights
All Individual Drugs Already Approved

Summary

This trialis researching if nitrous oxide can be used to reduce symptoms of Major Depressive Disorder (MDD). A single dose of nitrous oxide may have a fast and long-lasting effect and is safer to administer than other alternatives.

Eligible Conditions
  • Depression
  • Schizophrenia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 24 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and at 24 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in HDRS-21 score
Secondary study objectives
Computerized Adaptive Test-Depression Inventory (CAT-DI)
Computerized Adaptive Test-Suicide Scale (CAT-SS)
Dose effect of nitrous oxide using treatment-by-dose interaction term in a logistic regression model
+5 more
Other study objectives
Adverse events

Side effects data

From 2018 Phase 4 trial • 63 Patients • NCT03085563
7%
hypoxia
2%
paradoxical reaction
100%
80%
60%
40%
20%
0%
Study treatment Arm
Intranasal Midazolam
Nitrous Oxide

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Nitrous Oxide 50% or 25%Experimental Treatment1 Intervention
Nitrous oxide at an inhaled concentration of 50% or 25%
Group II: PlaceboPlacebo Group1 Intervention
Oxygen-air mixture
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Nitrous oxide
FDA approved

Find a Location

Who is running the clinical trial?

Bayside HealthLead Sponsor
111 Previous Clinical Trials
35,674 Total Patients Enrolled
5 Trials studying Depression
318 Patients Enrolled for Depression
Paul Myles, MDPrincipal InvestigatorThe Alfred
1 Previous Clinical Trials
172 Total Patients Enrolled
1 Trials studying Depression
172 Patients Enrolled for Depression

Media Library

Nitrous Oxide (NMDA-antagonist) Clinical Trial Eligibility Overview. Trial Name: NCT03869736 — Phase 2
Depression Research Study Groups: Nitrous Oxide 50% or 25%, Placebo
Depression Clinical Trial 2023: Nitrous Oxide Highlights & Side Effects. Trial Name: NCT03869736 — Phase 2
Nitrous Oxide (NMDA-antagonist) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03869736 — Phase 2
Depression Patient Testimony for trial: Trial Name: NCT03869736 — Phase 2
~25 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top